Search Results - "Miller, D. Michael"

TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy by Lim, So-Yon, Osuna, Christa E, Hraber, Peter T, Hesselgesser, Joe, Gerold, Jeffrey M, Barnes, Tiffany L, Sanisetty, Srisowmya, Seaman, Michael S, Lewis, Mark G, Geleziunas, Romas, Miller, Michael D, Cihlar, Tomas, Lee, William A, Hill, Alison L, Whitney, James B

“…Antiretroviral therapy (ART) can halt HIV-1 replication but fails to target the long-lived latent viral reservoir. Several pharmacological compounds have been…”
Get more information

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations by Feng, Meizhen, Sachs, Nancy A, Xu, Min, Grobler, Jay, Blair, Wade, Hazuda, Daria J, Miller, Michael D, Lai, Ming-Tain

“…Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase…”
Get full text

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein by Lawitz, Eric J, Dvory-Sobol, Hadas, Doehle, Brian P, Worth, Angela S, McNally, John, Brainard, Diana M, Link, John O, Miller, Michael D, Mo, Hongmei

“…Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to…”
Get full text

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir by Wyles, David, Dvory-Sobol, Hadas, Svarovskaia, Evguenia S, Doehle, Brian P, Martin, Ross, Afdhal, Nezam H, Kowdley, Kris V, Lawitz, Eric, Brainard, Diana M, Miller, Michael D, Mo, Hongmei, Gane, Edward J

“…Graphical abstract…”
Get full text

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions by Svarovskaia, Evguenia S., Gane, Edward, Dvory-Sobol, Hadas, Martin, Ross, Doehle, Brian, Hedskog, Charlotte, Jacobson, Ira M., Nelson, David R., Lawitz, Eric, Brainard, Diana M., McHutchison, John G., Miller, Michael D., Mo, Hongmei

“…Background. Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration…”
Get full text

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial by Lennox, Jeffrey L, Prof, DeJesus, Edwin, MD, Lazzarin, Adriano, Prof, Pollard, Richard B, Prof, Madruga, Jose Valdez Ramalho, MD, Berger, Daniel S, MD, Zhao, Jing, PhD, Xu, Xia, PhD, Williams-Diaz, Angela, BS, Rodgers, Anthony J, MS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Sklar, Peter, Dr

“…Summary Background Use of raltegravir with optimum background therapy is effective and well tolerated in treatment-experienced patients with…”
Get full text

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 by Wong, Kelly A, Worth, Angela, Martin, Ross, Svarovskaia, Evguenia, Brainard, Diana M, Lawitz, Eric, Miller, Michael D, Mo, Hongmei

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor by LAI, Ming-Tain, MEIZHEN FENG, CAUCHON, Elizabeth, CAMPEAU, Louis-Charles, GROBLER, Jay, YOUWEI YAN, DUCHARME, Yves, COTE, Bernard, ASANTE-APPIAH, Ernest, HAZUDA, Daria J, MILLER, Michael D, FALGUEYRET, Jean-Pierre, TAWA, Paul, WITMER, Marc, DISTEFANO, Daniel, YUAN LI, BURCH, Jason, SACHS, Nancy, MEIQING LU

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques by Klatt, Nichole R, Canary, Lauren A, Sun, Xiaoyong, Vinton, Carol L, Funderburg, Nicholas T, Morcock, David R, Quiñones, Mariam, Deming, Clayton B, Perkins, Molly, Hazuda, Daria J, Miller, Michael D, Lederman, Michael M, Segre, Julie A, Lifson, Jeffrey D, Haddad, Elias K, Estes, Jacob D, Brenchley, Jason M

“…HIV infection results in gastrointestinal (GI) tract damage, microbial translocation, and immune activation, which are not completely ameliorated with…”
Get full text

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals by Procopio, Francesco Andrea, Fromentin, Rémi, Kulpa, Deanna A., Brehm, Jessica H., Bebin, Anne-Gaelle, Strain, Matthew C., Richman, Douglas D., O'Doherty, Una, Palmer, Sarah, Hecht, Frederick M., Hoh, Rebecca, Barnard, Richard J.O., Miller, Michael D., Hazuda, Daria J., Deeks, Steven G., Sékaly, Rafick-Pierre, Chomont, Nicolas

“…Quantifying latently infected cells is critical to evaluate the efficacy of therapeutic strategies aimed at reducing the size of the long-lived viral…”
Get full text

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin by Hedskog, Charlotte, Doehle, Brian, Chodavarapu, Krishna, Gontcharova, Viktoria, Crespo Garcia, Javier, De Knegt, Robert, Drenth, Joost P.H, McHutchison, John G., Brainard, Diana, Stamm, Luisa M., Miller, Michael D., Svarovskaia, Evguenia, Mo, Hongmei

“…To date, intergenotypic recombinant hepatitis C viruses (HCVs) and their treatment outcomes have not been well characterized. This study characterized 12 novel…”
Get full text

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency by Ingallinella, Paolo, Bianchi, Elisabetta, Ladwa, Neal A, Wang, Ying-Jie, Hrin, Renee, Veneziano, Maria, Bonelli, Fabio, Ketas, Thomas J, Moore, John P, Miller, Michael D, Pessi, Antonello

“…Peptides derived from the heptad repeat 2 (HR2) region of the HIV fusogenic protein gp41 are potent inhibitors of viral infection, and one of them,…”
Get full text

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness by ABRAM, Michael E, HLUHANICH, Rebecca M, SVAROVSKAIA, Evguenia S, MCCOLL, Damian J, WHITE, Kirsten L, MILLER, Michael D, GOODMAN, Derrick D, ANDREATTA, Kristen N, MARGOT, Nicolas A, LINDA YE, NIEDZIELA-MAJKA, Anita, BARNES, Tiffany L, NOVIKOV, Nikolai, XIAOWU CHEN

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials by Eron, Joseph J, Prof, Young, Benjamin, MD, Cooper, David A, Prof, Youle, Michael, MD, DeJesus, Edwin, MD, Andrade-Villanueva, Jaime, MD, Workman, Cassy, MD, Zajdenverg, Roberto, MD, Fätkenheuer, Gerd, Prof, Berger, Daniel S, MD, Kumar, Princy N, MD, Rodgers, Anthony J, MS, Shaughnessy, Melissa A, MS, Walker, Monica L, BS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Xu, Xia, PhD, Sklar, Peter, Dr

“…Summary Background To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might…”
Get full text

CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells by Klatt, Nichole R, Shudo, Emi, Ortiz, Alex M, Engram, Jessica C, Paiardini, Mirko, Lawson, Benton, Miller, Michael D, Else, James, Pandrea, Ivona, Estes, Jacob D, Apetrei, Cristian, Schmitz, Joern E, Ribeiro, Ruy M, Perelson, Alan S, Silvestri, Guido

“…While CD8+ T cells are clearly important in controlling virus replication during HIV and SIV infections, the mechanisms underlying this antiviral effect remain…”
Get full text

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome by Abram, Michael E, Ram, Renee R, Margot, Nicolas A, Barnes, Tiffany L, White, Kirsten L, Callebaut, Christian, Miller, Michael D

“…T97A is an HIV-1 integrase polymorphism associated with integrase strand transfer inhibitor (INSTI) resistance. Using pooled data from 16 clinical studies, we…”
Get full text

Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy by Svarovskaia, Evguenia S, Martin, Ross, McHutchison, John G, Miller, Michael D, Mo, Hongmei

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat by MARGOT, Nicolas A, GIBBS, Craig S, MILLER, Michael D

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness by Kulkarni, Rima, Babaoglu, Kerim, Lansdon, Eric B, Rimsky, Laurence, Van Eygen, Veerle, Picchio, Gaston, Svarovskaia, Evguenia, Miller, Michael D, White, Kirsten L

“…The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two…”
Get full text

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure by LI, Jonathan Z, PAREDES, Roger, RIBAUDO, Heather J, SVAROVSKAIA, Evguenia S, KOZAL, Michael J, HULLSIEK, Katherine H, MILLER, Michael D, BANGSBERG, David R, KURITZKES, Daniel R

“…To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI…”
Get full text